Skip to main content

Market Overview

Affimed To Study AFM24/SNK-01 Combo In Solid Tumor Settings

Share:
  • The FDA has signed off an investigational new drug application for Affimed NV (NASDAQ: AFMD) and NKMax America co-sponsored Phase 1/2a dose escalation and expansion study to evaluate AFM24 and SNK-01 in EGFR-expressing solid tumors.
  • The Phase 1/2a study will be an open-label, non-randomized, multi-center, US-only, dose-escalation trial to evaluate the combination, with the primary objective to establish the safety and the recommended Phase 2 dose.
  • The Phase 1 part will also assess pharmacokinetics, pharmacodynamics, and preliminary activity.
  • The Phase 2a portion of the study will evaluate the preliminary efficacy of AFM24 in patients with select solid tumor subtypes.
  • Credit Suisse analyst Brad Canino initiates coverage on Affimed with an Outperform rating and a Price Target of $15.
  • Price Action: AFMD shares are up 6.5% at $7.82 in the market trading session on the last check Wednesday.

Latest Ratings for AFMD

DateFirmActionFromTo
Mar 2021Credit SuisseInitiates Coverage OnOutperform
Mar 2021Wells FargoMaintainsOverweight
Mar 2021SVB LeerinkMaintainsOutperform

View More Analyst Ratings for AFMD
View the Latest Analyst Ratings

 

Related Articles (AFMD)

View Comments and Join the Discussion!

Posted-In: Biotech News Health Care Initiation Small Cap FDA Analyst Ratings General

Latest Ratings

StockFirmActionPT
AMZNJP MorganMaintains4,600.0
STZOTR GlobalDowngrades
SYKESidoti & Co.Downgrades54.0
CAIB. Riley SecuritiesDowngrades
UALWolfe ResearchUpgrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com